Chimeric antigen receptor (CAR-T) cell treatment is an immunotherapy in which specialists gather resistant cells, alter them in a research facility, and give them the ability to kill malignant cells. The therapy involves removal of T cells from patient’s blood followed by addition of a gene receptor in the lab. Finally, it is injected back into the patient and stay in the body as living medications.
Immune system microorganisms lay the foundation of CAR-T cell treatment. Lymphocytes are the workhorses of resistant framework and assume a critical part in coordinating the insusceptible reaction and killing cells contaminated by microbes. In CAR-T cell treatment, blood is drawn from the patient and the T-cells are isolated out. In the research facility, an incapacitated infection is then used to hereditarily design the T-cells to deliver illusory antigen receptors (CARs) on their surface. These receptors are engineered and do not exist normally. Once injected into the patient, these CARs empower the T cells to link with the antigen (explicit protein) on the tumor cell prompting removal of the tumor.
COVID-19 Impact Analysis
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global CAR-T cell immunotherapy market.
Top Impacting Factors
Rise in the research and development of CD19 coupled with rise of latest technologically integrated biotechnology centers bound to boost market growth for CAR-T cell immunotherapy market.
Increase in awareness of CAR-T cells, which are now being labelled as potential mechanisms toward prevention and cure of tumors are anticipated to drive growth of CART-T cell immunotherapy market.
Strong presence of regional biotechnology players in India and China coupled with rising healthcare spending and favorable reimbursement policies in various regions are anticipated to drive the market growth for CAR-T cell immunotherapy.
However, lack of awareness associated with CAR-T cells in underdeveloped regions with low literacy rates coupled with lack of skilled biotechnology specialists is anticipated to restrict market growth for CAR-T cell immunotherapy market.
Additionally, higher costs associated with research and development of CART-T cell immunotherapy is anticipated to restrict market growth in underdeveloped and low per capita income economies.
Key Market Trends
- U.S. is expected to dominate the global market, owing rising incidents of chronic illness. In the U.S. alone, there were approximately a million new cancer cases analyzed in 2019. This coupled with advanced healthcare facility and favorable government support will help the U.S. to dominate the market.
- Europe is the second largest CAR T cell treatment market, owing to rise in prevalence of hematologic cancer such as leukemia, lymphoma, and myeloma and presence of global pharmaceutical players in the region.
- Further, China and India are anticipated to witness huge market traction, owing to developing healthcare infrastructure and rise in disposable income coupled with huge patient pool. Additionally, presence of significant market players is expected to support the market development during the forecast period.
- However, Africa and the Middle East are expected to witness stagnant growth due to unavailability of efficient medical infrastructure in the region coupled with lack of government support.
Key Benefits of the Report
- This study presents the analytical depiction of the CAR T-cell Immunotherapy industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the CAR T-cell Immunotherapy market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the CAR T-Cell Immunotherapy Market Report
- Which are the leading players active in the CAR T-cell immunotherapy market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the CAR T-cell immunotherapy market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is CAR T-cell immunotherapy?
- What is the CAR T-cell immunotherapy market prediction in the future?
- What are the current trends and predicted trends?
CAR T-Cell Immunotherapy Market Report Highlights
| Aspects | Details |
 By Product |
|
 By Application |
|
 By Target Antigen |
|
 By End Users |
|
 By Region |
|
 Key Market Players | Guangzhou Xiangxue Pharmaceutical, Atara Biotherapeutics, CARSGEN Therapeutics, Ltd, Pfizer, Bristol Myers Squibb, Novartis, Carina Biotech, Cellectis, Sorrento Therapeutics, Kite Pharma, Legend Biotech, Juno Therapeutics |
Loading Table Of Content...
